Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DUVQ | ISIN: FR0013269123 | Ticker-Symbol: BYNN
Tradegate
21.01.25
11:43 Uhr
24,900 Euro
+0,640
+2,64 %
1-Jahres-Chart
RUBIS SCA Chart 1 Jahr
5-Tage-Chart
RUBIS SCA 5-Tage-Chart
RealtimeGeldBriefZeit
24,88024,92011:50
24,92024,94011:50
GlobeNewswire (Europe)
502 Leser
Artikel bewerten:
(2)

RUBIS: Photosol Day 2024: Powering ahead - Heading for value-creating growth and targeting more than 2.5 GWp secured portfolio by 2027

Finanznachrichten News


Paris, 17 September 2024, 7.00 am (CET)

Rubis is organising today, 17 September 2024, in Paris (France), its "Photosol Day". During this event dedicated to Photosol, Clarisse Gobin-Swiecznik (Managing Partner at Rubis), Robin Ucelli and David Guinard (co-founders and, respectively, Chairman and CEO of Photosol), along with other members of Rubis and Photosol management, will present a comprehensive analysis of the evolution of the photovoltaic markets, Photosol's positioning, and the mid-term ambitions for the Company.

On this occasion the Managing Partners stated:"At a time when the European market is being transformed to address energy security by decarbonising production, Rubis is powering ahead to lead the way as a global energy service provider. With a 30-year track record of value-creating growth and strategic acquisitions, and a robust balance sheet, Rubis has chosen to seize the opportunities created by this transition, thus consolidating its long-term vision to secure the Group's future by operating in these new segments and markets. The acquisition of Photosol was a pivotal step forward, combining our extensive expertise with Photosol's entrepreneurial spirit and robust solar energy track record. This strategic move enables us to meet the evolving demand for energy, extract synergies, and will deliver substantial value to our stakeholders over the long term".

2027 ambitions:

  • Secured portfolio1 above 2.5 GWp
  • Consolidated EBITDA2: €50-55m, of which c.10% EBITDA contribution from farm-down initiatives
    • Power EBITDA3: €80-85m
    • Secured EBITDA4: €150-200m

The delays in grid connection times, that we have been mentioning since March 2023 are affecting the commissioning dates of some of our plants, thereby delaying our initial target of 1 GWp in operation by 2025. However, to date, the secured portfolio is in line with the 3.5 GWp in operation in 2030.

These targets will be achieved building upon the following:

A fertile ground for growth: The renewable energy sector is at a critical juncture, driven by soaring electricity demand, strong European green deal policies, and a push for energy sovereignty. Solar energy, now the most cost-effective renewable option, is well-positioned to capitalise on these trends. It represents a prime opportunity for significant value-creating growth in solar power and renewables. The favourable funding environment further supports ambitious expansion plans in the solar sector.

A well-thought positioning: Considering its particular focus on ground-mounted solar plants, Photosol aligns seamlessly with the Group's strategic objectives. With a proven track record and a robust project pipeline, Photosol demonstrates a solid level of reliability and expertise. Its combination of entrepreneurial spirit, experienced teams, and financial discipline helps support long-term value creation. This alignment in culture, operations, and finance underscores the strong potential of this union.

A well-established firm with unique photovoltaic strengths: Photosol manages every stage of the value chain, from project development to energy production. With a secured portfolio of c. 1 GWp today, and a pipeline of c. 5 GWp, the growth potential is important. Cash flows generated are steady and predictable and constitute a solid foundation for future growth.

A clear roadmap to accelerate diversification: France serves as Photosol's stronghold, providing a stable base with long-term revenue streams and secure financing. This robust foundation enables leveraging extensive experience for international expansion. The focus will extend to selected countries: Italy, Spain, Central and Eastern Europe. This strategic approach supports long-term value-creating growth.

Photosol Day documents will be available on Rubis website: https://www.rubis.fr/.
The live or recorded webcast can be viewed via the following link
https://channel.royalcast.com/rubisfr/#!/rubisfr/20240917_1

Press Contact Analyst Contact
RUBIS - Communication department RUBIS - Clémence Mignot-Dupeyrot, Head of IR
Tel: +33 (0)1 44 17 95 95

presse@rubis.fr (mailto:presse@rubis.fr)
Tel: +33 (0)1 45 01 87 44

investors@rubis.fr (mailto:investors@rubis.fr)



1 Includes ready to build, under construction and in operation capacities.

2 EBITDA reported in Rubis Group consolidated financial statements.

3 Aggregated EBITDA from operating PV through electricity sales.

4 Illustrative EBITDA coming from secured portfolio.

Attachment

  • RUBIS: Photosol Day 2024: Powering ahead - Heading for value-creating growth and targeting more than 2.5 GWp secured portfolio by 2027 (https://ml-eu.globenewswire.com/Resource/Download/720d7b9d-2561-438b-8d2c-52115b15cb97)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.